Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced significant progress in its oncology pipeline with the advancement of four candidates to late-stage trials that are currently enrolling participants. The first molecule is the LSD1 inhibitor bomedemstat, which is being developed for the treatment of essential thrombocythemia (ET). Nemtabrutinib, a BTK inhibitor, is targeting chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). MSD is also developing MK-2870, a TROP2-directed antibody drug conjugate (ADC) in collaboration with Kelun-Biotech (HKG: 6990), for non-small cell lung cancer (NSCLC) and endometrial carcinoma. Additionally, the CYP11A1 inhibitor MK-5684, part of a partnership with Orion (HEL: ORNBV), is being investigated as a therapy for metastatic castration-resistant prostate cancer (mCRPC).
These developments underscore MSD’s commitment to advancing innovative therapies in oncology, aiming to address unmet needs across various cancer types.- Flcube.com
